Browse Newsroom

Insulife in Finansavisen - Sting Without Fear of Needles

January 25, 2022

Åge Nærdal, InsuLife Co-Founder & CEO along with Petter W. Bjornstad, Co-Founder and Chief Commercial Officer were interviewed for an article that appeared in Finansavisen.no on January 14, 2022, where they discussed InsuLife's investigational medicinal spray-on-the-skin insulin.

Read the full article in Norwegian here: https://finansavisen.no/lordag/gruenderintervjuet/2022/01/14/7800359/age-naerdal-og-petter-bjornstad-i-insulife-utvikler-et-insulin-som-skal-smores-pa-huden

Article Highlights

• Insulife will allow for diabetics to get insulin through transdermal application – no needles needed.
• Insulife has raised NOK 13 million (at time of article) and is currently raising NOK 50 million (5.75mUSD) to build the organization and start the clinical studies in Norway and the USA.
• InsuLife is ready for clinical studies, and it plans to soon conduct trials on healthy people as well as people with type 1 diabetes at the University of Oslo.
• InsuLife aspires to make insulin available to the masses, including developing countries.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental Levellor™ spray-based insulin to market.
Learn More
© Copyright 2022 - InsuLife AS, All Rights Reserved